This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021. https://doi.org/10.1007/s40257-021-00598-4.
Smith CH, Yiu ZZN, Bale T, Burden AD, Coates LC, Edwards W, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628–37.
Reid C, Cordingley L, Warren RB, Griffiths CEM. Progress to date in advancing stratified medicine in psoriasis. Am J Clin Dermatol. 2020;21(5):619–26.
Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183(2):294–302.
Warren RB, Brnabic A, Saure D, Langley RG, See K, Wu JJ, et al. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. Br J Dermatol. 2018;178(5):1064–71.
Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935–45.
Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887–92.
Page MJ, McKenzie JE, Kirkham J, Dwan K, Kramer S, Green S, et al. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. Cochrane Database Syst Rev. 2014;(10):MR000035.
Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, et al. Randomized trial replication using observational data for comparative effectiveness of secukinumab and ustekinumab in psoriasis: a study from the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA Dermatol. 2021;157(1):66–73.
Iskandar IYK, Ashcroft DM, Warren RB, Lunt M, McElhone K, Smith CH, et al. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. Br J Dermatol. 2017;177(5):1410–21.
Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60-9.e9.
Shalom G, Cohen AD, Feldhamer I, Comaneshter D, Freud T, Pavlovsky L. Drug survival in patients with psoriasis is associated with the availability of biologic medications. J Eur Acad Dermatol Venereol. 2020;34(7):1524–8.
Thaci D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–9.
Hernan MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758–64.
Observational studies in a learning health system: workshop summary. National Academies Press, Washington, DC; 2013.
Yael Renert-Yuval, James G. Krueger, and Jonathan N. Tobin were supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health Clinical and Translational Science Award program through The Rockefeller University, Grant no. UL1TR001866.
Conflict of interest
James G. Krueger has received research support (grants paid to his institution) and/or personal fees from Pfizer, Amgen, Janssen, Lilly, Merck, Novartis, Kadmon, Dermira, Boehringer, Innovaderm, Kyowa, BMS, Serono, Biogen Idec, Delenex, AbbVie, Sanofi, Baxter, Paraxel, Xenoport, and Kineta. Jonathan N. Tobin has received research support (grants paid to his institution) and/or personal fees from National Institutes of Health, Agency for Healthcare Research and Quality, Patient-Centered Outcomes Research Institute, Bio-Ascend LLC, Regional Cancer Care Associates, Washington University in St. Louis, Astra Zeneca, Merck, Bristol Myers Squibb, Purdue Pharma, and Syneos. Yael Renert-Yuval has no conflicts of interest that are directly relevant to the content of this letter.
Consent to participate
Consent for publication
Availability of data and material
This comment refers to the article available at: https://doi.org/10.1007/s40257-021-00598-4
About this article
Cite this article
Renert-Yuval, Y., Krueger, J.G. & Tobin, J.N. The Busy Arena of Psoriasis Treatments: Improving the Clinician’s Ability to Make the Right Therapeutic Choice. Am J Clin Dermatol (2021). https://doi.org/10.1007/s40257-021-00617-4